GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

Home・Akciju saraksts・Camurus AB

Camurus AB

Atvērts

599 -1.56

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

594

Max

608.5

Galvenie mērījumi
By Trading Economics
Ienākumi	-99M 193M
Pārdošana	-108M 567M
P/E Sektora vidējais	46.937 76.798
EPS	3.19
Peļņas marža	33.972
Darbinieki	280
EBITDA	-62M 253M

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	432M 37B
Iepriekšējā atvēršanas cena	600.56
Iepriekšējā slēgšanas cena	599

Camurus AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 19. dec. 17:29 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

2025. g. 19. dec. 16:47 UTC

Galvenie tirgus virzītāji

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

2025. g. 19. dec. 16:10 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

2025. g. 21. dec. 23:51 UTC

Tirgus saruna

Oil Rises Amid Growing U.S.-Venezuela Tensions -- Market Talk

2025. g. 21. dec. 23:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 21. dec. 23:45 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 21. dec. 23:35 UTC

Tirgus saruna

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

2025. g. 19. dec. 22:33 UTC

Peļņas

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

2025. g. 19. dec. 22:19 UTC

Peļņas

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025. g. 19. dec. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 21:44 UTC

Peļņas

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 21:38 UTC

Peļņas

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

2025. g. 19. dec. 21:00 UTC

Tirgus saruna

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

2025. g. 19. dec. 20:23 UTC

Tirgus saruna

Oil Futures End Down Week on Up Note -- Market Talk

2025. g. 19. dec. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

2025. g. 19. dec. 18:38 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

2025. g. 19. dec. 18:00 UTC

Tirgus saruna

Peļņas

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

2025. g. 19. dec. 17:41 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 17:24 UTC

Tirgus saruna

Peļņas

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 19. dec. 16:29 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

2025. g. 19. dec. 16:20 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

2025. g. 19. dec. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

2025. g. 19. dec. 16:18 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

2025. g. 19. dec. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 16:04 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 15:37 UTC

Tirgus saruna

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

Salīdzinājums

Cenas izmaiņa

Camurus AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.